Pridopidine for Levodopa-Induced Dyskinesia in Parkinson’s Disease

This is a multicenter, randomized, double-blind, placebo-controlled, three-arm parallel group study to evaluate the efficacy, safety, and pharmacokinetics (PK) of pridopidine versus placebo for the treatment of Levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.